KR20100049644A - 안드로겐 수용체 조절제로서의 피롤리딘-2-온 유도체 - Google Patents

안드로겐 수용체 조절제로서의 피롤리딘-2-온 유도체 Download PDF

Info

Publication number
KR20100049644A
KR20100049644A KR1020107005062A KR20107005062A KR20100049644A KR 20100049644 A KR20100049644 A KR 20100049644A KR 1020107005062 A KR1020107005062 A KR 1020107005062A KR 20107005062 A KR20107005062 A KR 20107005062A KR 20100049644 A KR20100049644 A KR 20100049644A
Authority
KR
South Korea
Prior art keywords
atom
group
substituent
optionally
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020107005062A
Other languages
English (en)
Korean (ko)
Inventor
아츠시 하스오카
Original Assignee
다케다 야쿠힌 고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다케다 야쿠힌 고교 가부시키가이샤 filed Critical 다케다 야쿠힌 고교 가부시키가이샤
Publication of KR20100049644A publication Critical patent/KR20100049644A/ko
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/54—Spiro-condensed

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020107005062A 2007-08-07 2008-08-06 안드로겐 수용체 조절제로서의 피롤리딘-2-온 유도체 Abandoned KR20100049644A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JPJP-P-2007-205966 2007-08-07
JP2007205966 2007-08-07
JP2007299658 2007-11-19
JPJP-P-2007-299658 2007-11-19

Publications (1)

Publication Number Publication Date
KR20100049644A true KR20100049644A (ko) 2010-05-12

Family

ID=40329363

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107005062A Abandoned KR20100049644A (ko) 2007-08-07 2008-08-06 안드로겐 수용체 조절제로서의 피롤리딘-2-온 유도체

Country Status (34)

Country Link
US (2) US8420694B2 (https=)
EP (1) EP2176220B1 (https=)
JP (1) JP5292390B2 (https=)
KR (1) KR20100049644A (https=)
CN (1) CN101821235B (https=)
AR (1) AR067823A1 (https=)
AU (1) AU2008284662B2 (https=)
BR (1) BRPI0814957B8 (https=)
CA (1) CA2695852C (https=)
CL (1) CL2008002313A1 (https=)
CO (1) CO6160326A2 (https=)
CR (1) CR11266A (https=)
CY (1) CY1114067T1 (https=)
DK (1) DK2176220T3 (https=)
DO (1) DOP2010000053A (https=)
EA (1) EA017429B1 (https=)
ES (1) ES2406685T3 (https=)
GE (1) GEP20125571B (https=)
HR (1) HRP20130374T1 (https=)
JO (1) JO2864B1 (https=)
MA (1) MA31639B1 (https=)
ME (1) ME01579B (https=)
MX (1) MX2010001484A (https=)
MY (1) MY159910A (https=)
NZ (1) NZ583624A (https=)
PE (1) PE20090899A1 (https=)
PL (1) PL2176220T3 (https=)
PT (1) PT2176220E (https=)
RS (1) RS52812B (https=)
SI (1) SI2176220T1 (https=)
TN (1) TN2010000062A1 (https=)
TW (1) TWI418543B (https=)
WO (1) WO2009020234A2 (https=)
ZA (1) ZA201001289B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015163604A1 (ko) * 2014-04-24 2015-10-29 동아에스티 주식회사 옥사졸리딘계 화합물 및 이를 포함하는 선택적 안드로겐 수용체 효능제

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME01579B (me) * 2007-08-07 2014-09-20 Takeda Pharmaceuticals Co Derivati pirolidin-2-ona kao modulatori androgenskih receptora
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
CA2716320C (en) * 2008-02-22 2014-01-28 Radius Health, Inc. Selective androgen receptor modulators
PE20091653A1 (es) * 2008-03-26 2009-11-14 Takeda Pharmaceutical Derivados sustituidos de pirazol y su uso
AU2011212813B2 (en) 2010-02-04 2014-10-23 Radius Health, Inc. Selective androgen receptor modulators
HUE030072T2 (en) 2010-05-12 2017-04-28 Radius Health Inc Therapeutic prescriptions
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
US9133182B2 (en) 2010-09-28 2015-09-15 Radius Health, Inc. Selective androgen receptor modulators
EP2834216A1 (en) * 2012-04-04 2015-02-11 Catylix Inc. Selective androgen receptor modulators
EP3158995B1 (en) 2012-08-09 2018-05-23 Dynamis Therapeutics, Inc. Meglumine for reducing high triglyceride levels
KR102069008B1 (ko) * 2012-09-21 2020-02-11 메르크 파텐트 게엠베하 C-c 삼중 결합을 갖는 화합물 및 액정 혼합물에서 이의 용도
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
ES3055185T3 (en) 2014-03-28 2026-02-10 Univ Duke Treatment of an estrogen receptor positive breast cancer using a selective estrogen receptor modulator
CN103951688B (zh) * 2014-05-06 2016-04-20 成都安斯利生物医药有限公司 一种制备3,5-二氟-4-甲基苯硼酸的方法
MX389702B (es) 2016-06-22 2025-03-20 Ellipses Pharma Ltd Compuestos para usarse en el tratamiento de cancer de mama que expresa el receptor de androgenos (ar+).
JP7481115B2 (ja) 2017-01-05 2024-05-10 ラジウス ファーマシューティカルズ，インコーポレイテッド Ｒａｄ１９０１－２ｈｃｌの多形性形態
MX2020013713A (es) 2018-07-04 2021-03-02 Radius Pharmaceuticals Inc Formas polimorficas de rad1901-2hcl.
BR112021013557A2 (pt) 2019-01-11 2021-09-21 Grünenthal GmbH Amidas de pirrolidina substituídas iii
EP3924328A1 (en) 2019-02-12 2021-12-22 Radius Pharmaceuticals, Inc. Processes and compounds
CN110204505B (zh) * 2019-05-31 2023-02-03 荆门医药工业技术研究院 (s)-3-苄氧羰基-4-异丙基-2,5-恶唑烷二酮的制备工艺
US20230012570A1 (en) * 2019-11-20 2023-01-19 Medshine Discovery Inc. Bicyclic compound used as selective androgen receptor modulator

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4141399A1 (de) 1991-12-16 1993-06-17 Bayer Ag 4-(substituierte)amino-3-arylpyrrolinon-derivate
CN1129581C (zh) * 1998-09-22 2003-12-03 山之内制药株式会社 氰基苯基衍生物
US6258833B1 (en) 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US7026500B2 (en) 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
JP2002088073A (ja) 2000-09-08 2002-03-27 Yamanouchi Pharmaceut Co Ltd 抗アンドロゲン剤
FR2817472B1 (fr) 2000-12-06 2003-01-03 Oreal Composition de teinture d'oxydation a base de 1-(4-aminophenyl)pyrrolidines substituees au moins en position 2 et 3 et procede de teinture de mise en oeuvre
DK1463497T3 (da) 2001-12-06 2012-01-30 Gtx Inc Behandling af muskelsvind med selektive androgenreceptormodulatorer
JP4316232B2 (ja) 2001-12-28 2009-08-19 武田薬品工業株式会社 アンドロゲン受容体拮抗剤
AU2002367424A1 (en) * 2001-12-28 2003-07-24 Takeda Chemical Industries, Ltd. Androgen receptor antagonists
JP2005529952A (ja) 2002-06-17 2005-10-06 ユニバーシティ・オブ・テネシー・リサーチ・ファウンデーション Ｎ架橋選択的アンドロゲン受容体修飾物質及びその使用方法
PL375042A1 (en) 2002-08-12 2005-11-14 Takeda Pharmaceutical Company Limited Fused benzene derivative and use
GB0402492D0 (en) 2004-02-04 2004-03-10 Pfizer Ltd Pharmaceutically active compounds
US8519158B2 (en) * 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
MXPA06013115A (es) * 2004-05-11 2007-02-28 Pfizer Prod Inc Derivados de benzonitrilo para tratar la fragilidad musculoesqueletica.
EP1756101A2 (en) 2004-05-17 2007-02-28 Acadia Pharmaceuticals Inc. Androgen receptor modulators and method of treating disease using the same
PL1753417T3 (pl) 2004-06-07 2012-09-28 Univ Tennessee Res Found Selektywny modulator receptora androgenowego i jego zastosowania medyczne
CN101119993B (zh) 2005-01-10 2015-03-04 阿卡蒂亚药品公司 作为选择性雄激素受体调节剂的氨基苯基衍生物
TW200724139A (en) 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
PL1891038T3 (pl) 2005-05-13 2009-04-30 Lilly Co Eli Podstawione n-arylopirolidyny jako selektywne modulatory receptora androgenowego
JP5070054B2 (ja) 2005-08-01 2012-11-07 武田薬品工業株式会社 環状アミン化合物
US20090042857A1 (en) * 2006-02-20 2009-02-12 Masuo Yamaoka Novel Pharmaceutical
BRPI0713198A2 (pt) 2006-07-19 2012-10-16 Osurf Ohio State University Res Foundation modulares seletivos de receptores de androgênio, seus análogos e derivados, e seus usos
KR20090034395A (ko) * 2006-07-26 2009-04-07 노파르티스 아게 운데카프레닐 피로포스페이트 합성효소의 억제제
JP5241507B2 (ja) 2006-11-30 2013-07-17 武田薬品工業株式会社 環状アミン化合物
ME01579B (me) * 2007-08-07 2014-09-20 Takeda Pharmaceuticals Co Derivati pirolidin-2-ona kao modulatori androgenskih receptora

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015163604A1 (ko) * 2014-04-24 2015-10-29 동아에스티 주식회사 옥사졸리딘계 화합물 및 이를 포함하는 선택적 안드로겐 수용체 효능제
US9809583B2 (en) 2014-04-24 2017-11-07 Dong-A St Co., Ltd. Oxazolidine-based compound and selective androgen receptor agonist comprising same
RU2702001C2 (ru) * 2014-04-24 2019-10-03 Донг-А Ст Ко., Лтд. Соединение на основе оксазолидина и содержащий его селективный агонист андрогенового рецептора
RU2702001C9 (ru) * 2014-04-24 2019-11-25 Донг-А Ст Ко., Лтд. Соединение на основе оксазолидина и содержащий его селективный агонист андрогенового рецептора

Also Published As

Publication number Publication date
EA017429B1 (ru) 2012-12-28
PT2176220E (pt) 2013-04-09
PL2176220T3 (pl) 2013-08-30
CL2008002313A1 (es) 2009-05-15
AR067823A1 (es) 2009-10-21
NZ583624A (en) 2012-06-29
MA31639B1 (fr) 2010-08-02
JP5292390B2 (ja) 2013-09-18
HK1143972A1 (en) 2011-01-21
BRPI0814957B1 (pt) 2019-12-03
AU2008284662A1 (en) 2009-02-12
AU2008284662B2 (en) 2013-07-25
HRP20130374T1 (en) 2013-05-31
ME01579B (me) 2014-09-20
US20110098336A1 (en) 2011-04-28
CA2695852A1 (en) 2009-02-12
BRPI0814957A2 (pt) 2015-02-03
ZA201001289B (en) 2011-04-28
GEP20125571B (en) 2012-07-10
US20090042967A1 (en) 2009-02-12
EP2176220B1 (en) 2013-03-27
US8420694B2 (en) 2013-04-16
TW200916439A (en) 2009-04-16
RS52812B (sr) 2013-10-31
CN101821235A (zh) 2010-09-01
CN101821235B (zh) 2012-11-14
CR11266A (es) 2010-03-22
PE20090899A1 (es) 2009-08-06
DK2176220T3 (da) 2013-06-10
MY159910A (en) 2017-02-15
ES2406685T3 (es) 2013-06-07
EA201070246A1 (ru) 2010-08-30
SI2176220T1 (sl) 2013-05-31
WO2009020234A2 (en) 2009-02-12
TN2010000062A1 (en) 2011-09-26
CO6160326A2 (es) 2010-05-20
TWI418543B (zh) 2013-12-11
EP2176220A2 (en) 2010-04-21
JP2010535704A (ja) 2010-11-25
US7834051B2 (en) 2010-11-16
WO2009020234A3 (en) 2009-04-16
JO2864B1 (en) 2015-03-15
CY1114067T1 (el) 2016-07-27
MX2010001484A (es) 2010-03-04
BRPI0814957B8 (pt) 2021-05-25
DOP2010000053A (es) 2010-07-15
CA2695852C (en) 2017-01-03

Similar Documents

Publication Publication Date Title
KR20100049644A (ko) 안드로겐 수용체 조절제로서의 피롤리딘-2-온 유도체
JP5070054B2 (ja) 環状アミン化合物
WO2009133861A1 (ja) 環状アミン化合物
JPWO2007097289A1 (ja) 新規医薬
WO2004016576A1 (ja) 縮合ベンゼン誘導体および用途
JP5241507B2 (ja) 環状アミン化合物
JP4426792B2 (ja) 縮合ベンゼン誘導体および用途
HK1143972B (en) Pyrrolidin-2-one derivatives as androgen receptor modulator

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee

St.27 status event code: A-2-2-U10-U14-oth-PC1904

St.27 status event code: N-2-6-B10-B12-nap-PC1904

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000